{"id":"NCT00828204","sponsor":"Biogen","briefTitle":"Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects","officialTitle":"An Open-Label, Multicenter Study to Evaluate the Safe and Effective Use of the Single-Use Autoinjector With an Avonex® Prefilled Syringe in Multiple Sclerosis Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01","primaryCompletion":"2010-07","completion":"2010-10","firstPosted":"2009-01-23","resultsPosted":"2011-08-09","lastUpdate":"2014-06-03"},"enrollment":95,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":null},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DEVICE","name":"single-use autoinjector with a prefilled liquid Avonex syringe","otherNames":[]},{"type":"DEVICE","name":"Avonex prefilled syringe via manual IM injection","otherNames":[]},{"type":"DRUG","name":"BG9418 (interferon beta-1a)","otherNames":["Avonex"]}],"arms":[{"label":"Avonex Single-Use Autoinjector","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study was to evaluate the safe and effective use of the single-use autoinjector for the intramuscular (IM) delivery of liquid Avonex® (interferon beta-1a) in participants with multiple sclerosis (MS).","primaryOutcome":{"measure":"Percentage of Participants in the Main Subset With Overall Success Using the Avonex Single-Use Autoinjector","timeFrame":"Day 22","effectByArm":[{"arm":"Avonex Single-Use Autoinjector: Main Subset","deltaMin":89,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":16,"countries":["United States"]},"refs":{"pmids":["21999176"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":72},"commonTop":["Injection Site Pain","Injection Site Haematoma","Influenza Like Illness","Injection Site Erythema","Anxiety"]}}